Home Cart Sign in  
Chemical Structure| 55981-09-4 Chemical Structure| 55981-09-4

Structure of Nitazoxanide
CAS No.: 55981-09-4

Chemical Structure| 55981-09-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nitazoxanide is an inhibitor of pyruvate-ferredoxin oxidoreductase (PFOR), it's a FDA approved anti-parasitic drug.

Synonyms: NTZ; NSC 697855; Nitazoxanide, Alinia, Colufase, Daxon, Nitazoxamide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Phelelisiwe S. Dube ; Dylan Hart ; Lesetja J. Legoabe ; Audrey Jordaan ; Digby F. Warner ; Richard M. Beteck

Abstract: Nitrothiazole derivatives have been reported to exhibit activity against aerobic, anaerobic, and microaerophilic bacteria. This activity profile makes the nitrothiazole compound class an ideal lead source against Mycobacterium tuberculosis, which flourishes in varied environments with different oxygen concentrations. In this work, we investigated six nitrothiazole derivatives for antitubercular activity. The compounds exhibited potent activity, with compounds 9 and 10 possessing an equipotent MIC90 value of 0.24 µM. The compounds were investigated for cytotoxicity against HEK293 cells and hemolysis against red blood cells, and they demonstrated no cytotoxicity nor hemolytic effects, suggesting they possess inherent antitubercular activity.

Keywords: nitrothiazole ; Mannich bases ; antitubercular activity ; tuberculosis ; Mycobacterium tuberculosis

Purchased from AmBeed: ; ;

Frauke Assmus ; Jean-Sélim Driouich ; Rana Abdelnabi ; Laura Vangeel ; Franck Touret ; Ayorinde Adehin , et al.

Abstract: In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, baricitinib), others failed to show clinical efficacy. One reason is the lack of clear translational processes based on adequate preclinical profiling before clinical evaluation. Combined with limitations of existing in vitro and in vivo models, there is a need for a systematic approach to urgent antiviral drug development in the context of a global pandemic. We implemented a methodology to test repurposed and experimental drugs to generate robust preclinical evidence for further clinical development. This translational drug development platform comprises in vitro, ex vivo, and in vivo models of SARS-CoV-2, along with pharmacokinetic modeling and simulation approaches to evaluate exposure levels in plasma and target organs. Here, we provide examples of identified repurposed antiviral drugs tested within our multidisciplinary collaboration to highlight lessons learned in urgent antiviral drug development during the COVID-19 pandemic. Our data confirm the importance of assessing in vitro and in vivo potency in multiple assays to boost the translatability of pre-clinical data. The value of pharmacokinetic modeling and simulations for compound prioritization is also discussed. We advocate the need for a standardized translational drug development platform for mild-to-moderate COVID-19 to generate preclinical evidence in support of clinical trials. We propose clear prerequisites for progression of drug candidates for repurposing into clinical trials. Further research is needed to gain a deeper understanding of the scope and limitations of the presented translational drug development platform.

Keywords: COVID-19 ; drug repurposing ; translational medicine ; pandemics ; clinical trials

Purchased from AmBeed: ; ; ; ; ; ; ; ; 61718-82-9

Alternative Products

Product Details of Nitazoxanide

CAS No. :55981-09-4
Formula : C12H9N3O5S
M.W : 307.28
SMILES Code : CC(OC1=CC=CC=C1C(NC2=NC=C([N+]([O-])=O)S2)=O)=O
Synonyms :
NTZ; NSC 697855; Nitazoxanide, Alinia, Colufase, Daxon, Nitazoxamide
MDL No. :MFCD00416599
InChI Key :YQNQNVDNTFHQSW-UHFFFAOYSA-N
Pubchem ID :41684

Safety of Nitazoxanide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Marc-145 cells 20 μM 36 h Identified as significant inhibitors of PRRSV proliferation. PMC11156899
Prostate cancer cells expressing KLF5K369Q 0.1 μM 48 h To inhibit cell invasion and identify drugs... NTZ significantly suppressed the invasion of prostate cancer cells. PMC9945734
HCT-116 colon cancer cells and normal colon cells (FHC) 11.07 µM 48 h To examine the cytotoxic effects and induction of apoptosis in colon cancer cells. PMC8156814

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Colon cancer induced by dimethylhydrazine (DMH) Oral gavage 100 mg/kg and 200 mg/kg From the 7th week of induction of colonic cancer till the end of the therapeutic period (at the end of week 12) To evaluate the antitumor efficacy of nitazoxanide in a DMH-induced mouse model. PMC8156814

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00366236 Amebiasis PHASE3 COMPLETED 2025-11-05 University Hospital, Alexandri... More >>a, Egypt|Benha University Hospital, Benha, Egypt Less <<
NCT01074203 Hepatitis C Recurrence PHASE1 COMPLETED 2025-01-11 Mayo Clinic College of Medicin... More >>e, Rochester, Minnesota, 55905, United States Less <<
NCT00304356 Clostridium Enterocolitis|Pseu... More >>domembranous Colitis Less << PHASE3 COMPLETED 2025-01-07 Baylor College of Medicine, Ho... More >>uston, Texas, 77030, United States|Michael E. Debakey VA Medical Center, Houston, Texas, 77030, United States Less <<
NCT01326338 Diarrhea PHASE3 COMPLETED 2025-05-06 Regional Hospital of Cajamarca... More >>, Cajamarca, Peru Less <<
NCT00366730 Amebiasis PHASE3 COMPLETED 2025-11-05 University Hospital, Alexandri... More >>a, Egypt|Benha University Hospital, Benha, Egypt Less <<
NCT05116826 Moderate Hepatic Impairment|Se... More >>vere Hepatic Impairment|Liver Diseases Less << PHASE1 COMPLETED 2022-04-13 Panax Clinical Research, Miami... More >> Lakes, Florida, 33014, United States|Orlando Clinical Research Center, Orlando, Florida, 32802, United States Less <<
NCT06010992 Diabetes Mellitus, Type 2 PHASE2 RECRUITING 2025-01-01 Faculty of medicine, Tanta Uni... More >>versity, Tanta, El-Gharbia, 31527, Egypt|Faculty of Medicine, Menoufia University, Shibīn Al Kawm, Menoufia, 32511, Egypt Less <<
NCT00055107 HIV Infections|Cryptosporidios... More >>is Less << PHASE1|PHASE2 COMPLETED 2025-05-06 Stellenbosch Univ. CRS, Cape T... More >>own, 7505, South Africa|Siriraj Hospital Mahidol University CRS, Bangkok, 10700, Thailand Less <<
NCT00001081 Cryptosporidiosis|HIV Infectio... More >>ns Less << PHASE2 COMPLETED 1998-09-01 Cook County Hosp. CORE Ctr., C... More >>hicago, Illinois, 60612, United States Less <<
NCT05368935 Renal Impairment|Renal Disease... More >>|Kidney Disease Less << PHASE1 COMPLETED 2022-09-09 Panax Clinical Research, Miami... More >> Lakes, Florida, 33014, United States|Orlando Clinical Research Center, Orlando, Florida, 32802, United States Less <<
NCT00004986 Cryptosporidiosis|HIV Infectio... More >>ns Less << PHASE3 TERMINATED - Julie Ryner, Tampa, Florida, 3... More >>3607, United States Less <<
NCT00418639 Chronic Hepatitis C PHASE2 COMPLETED - Department of Tropical Medicin... More >>e & Infectious Diseases, Alexandria University, Alexandria, Egypt|Cairo Liver & GIT Center, Cairo, Egypt|Department of Tropical Medicine & Infectious Diseases, Tanta University School of Medicine, Tanta, Egypt Less <<
NCT01328925 Rotavirus Infection|Viral Gast... More >>roenteritis Due to Rotavirus Less << PHASE2 COMPLETED 2025-06-06 Cairo University Children's Ho... More >>spital, Cairo, Egypt Less <<
NCT01529073 HCV Coinfection|HIV Infection PHASE2 UNKNOWN 2025-02-15 H.U. Valme, Seville, 41014, Sp... More >>ain Less <<
NCT00002444 HIV Infections PHASE1 COMPLETED 1996-02-01 New York Hosp / Cornell Med Ct... More >>r, New York, New York, 10021, United States Less <<
NCT04382846 COVID|Corona Virus Infection PHASE3 RECRUITING 2030-12-01 Tanta University, Assiut Unive... More >>rsity, Tanta, 35111, Egypt|Sherief Abd-Elsalam, Tanta, Egypt Less <<
NCT00002158 Cryptosporidiosis|HIV Infectio... More >>ns Less << UNKNOWN - Romark Laboratories LC, Tampa,... More >> Florida, 33607, United States Less <<
NCT06049901 Metastatic Colorectal Cancer PHASE3 RECRUITING 2025-03-26 Tanta University Hospital, Tan... More >>ta, El-Gharbia Governorate, 31527, Egypt Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.25mL

0.65mL

0.33mL

16.27mL

3.25mL

1.63mL

32.54mL

6.51mL

3.25mL

References

 

Historical Records

Categories